Juventas Therapeutics to Present Top-Line Interim Results from Phase II STOP-HF Trial in Late-Breaking Oral Presentation at European Society of Cardiology Heart Failure Congress /PRNewswire-USNewswire/ -- Juventas Therapeutics today announced that top-line interim data from its ongoing Phase II STOP-HF study will be presented in a late-breaking ... (more)
http://ift.tt/1o2wK9u
http://ift.tt/1o2wK9u
No comments:
Post a Comment